Becton Dickinson EBITDA Margin 2010-2023 | BDX

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Becton Dickinson (BDX) over the last 10 years. The current EBITDA margin for Becton Dickinson as of December 31, 2023 is .
Becton Dickinson EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2023-12-31 $19.49B $4.25B 21.78%
2023-09-30 $19.37B $4.40B 22.71%
2023-06-30 $19.05B $4.53B 23.79%
2023-03-31 $18.81B $4.50B 23.95%
2022-12-31 $18.74B $4.43B 23.63%
2022-09-30 $18.87B $4.51B 23.91%
2022-06-30 $18.41B $4.11B 22.31%
2022-03-31 $18.38B $4.04B 22.01%
2021-12-31 $18.53B $3.92B 21.16%
2021-09-30 $19.13B $4.48B 23.42%
2021-06-30 $18.57B $4.01B 21.60%
2021-03-31 $17.82B $3.88B 21.76%
2020-12-31 $17.16B $3.79B 22.10%
2020-09-30 $16.07B $3.03B 18.83%
2020-06-30 $16.92B $3.50B 20.66%
2020-03-31 $17.41B $3.80B 21.83%
2019-12-31 $17.36B $3.60B 20.71%
2019-09-30 $17.29B $4.01B 23.21%
2019-06-30 $17.11B $4.49B 26.25%
2019-03-31 $17.04B $4.37B 25.65%
2018-12-31 $17.06B $4.41B 25.85%
2018-09-30 $15.98B $3.49B 21.82%
2018-06-30 $14.75B $3.12B 21.17%
2018-03-31 $13.50B $2.10B 15.54%
2017-12-31 $12.25B $2.06B 16.85%
2017-09-30 $12.09B $2.61B 21.58%
2017-06-30 $12.16B $2.20B 18.12%
2017-03-31 $12.32B $2.94B 23.83%
2016-12-31 $12.42B $2.98B 23.96%
2016-09-30 $12.48B $2.54B 20.38%
2016-06-30 $12.31B $2.78B 22.61%
2016-03-31 $12.23B $2.43B 19.88%
2015-12-31 $11.22B $2.12B 18.88%
2015-09-30 $10.28B $1.97B 19.11%
2015-06-30 $9.42B $1.91B 20.21%
2015-03-31 $8.46B $2.06B 24.30%
2014-12-31 $8.48B $2.14B 25.18%
2014-09-30 $8.45B $2.17B 25.67%
2014-06-30 $8.35B $1.84B 22.01%
2014-03-31 $8.24B $1.79B 21.77%
2013-12-31 $8.17B $1.80B 22.03%
2013-09-30 $8.05B $1.80B 22.36%
2013-06-30 $7.92B $2.10B 26.49%
2013-03-31 $7.85B $2.13B 27.09%
2012-12-31 $7.78B $2.12B 27.26%
2012-09-30 $7.71B $2.07B 26.84%
2012-06-30 $7.61B $2.05B 26.90%
2012-03-31 $7.58B $2.04B 26.94%
2011-12-31 $7.57B $2.09B 27.65%
2011-09-30 $7.58B $2.16B 28.48%
2011-06-30 $7.34B $2.10B 28.54%
2011-03-31 $7.22B $2.08B 28.82%
2010-12-31 $7.10B $2.06B 28.98%
2010-09-30 $7.12B $2.07B 29.11%
2010-06-30 $7.22B $2.14B 29.57%
2010-03-31 $7.21B $2.13B 29.58%
2009-12-31 $7.14B $2.07B 29.03%
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $67.638B $19.372B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $68.967B 18.46
West Pharmaceutical Services (WST) United States $27.235B 46.04
Cardinal Health (CAH) United States $26.315B 15.82
Align Technology (ALGN) United States $22.499B 45.37
Cooper (COO) United States $17.972B 27.19
Labcorp (LH) United States $16.950B 14.47
Henry Schein (HSIC) United States $9.104B 15.75
DENTSPLY SIRONA (XRAY) United States $6.325B 16.67
Merit Medical Systems (MMSI) United States $4.182B 23.93
Patterson (PDCO) United States $2.331B 11.17
STAAR Surgical (STAA) United States $2.267B 71.37
CONMED (CNMD) United States $2.237B 21.06
Atrion (ATRI) United States $0.708B 36.48
Lifevantage (LFVN) United States $0.086B 13.96
Pro-Dex (PDEX) United States $0.067B 25.33
Biolase (BIOL) United States $0.005B 0.00